# Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

> **NCT05076695** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 37 (estimated)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** trastuzumab
- **DRUG:** pyrotinib
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT05076695
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-15
- **Primary completion:** 2023-10-15
- **Final completion:** 2024-10-15
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05076695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05076695, "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05076695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*